Excorp Medical

Excorp Medical is a biotechnology company that specialized in the development of a bioartificial liver support system (BLSS) for patients suffering from acute liver failure. The company's core technology featured an extracorporeal hollow-fiber bioreactor seeded with primary porcine hepatocytes, designed to replicate the complex metabolic and synthetic functions of the human liver. This system was intended to provide temporary support, acting as a bridge to liver transplantation or facilitating the recovery of the patient's native liver. Excorp Medical progressed its BLSS through early-stage clinical trials, demonstrating the feasibility of using xenogeneic cells in a controlled clinical setting. The device was specifically targeted at patients with fulminant hepatic failure (FHF) who had limited treatment options. Although the company is no longer active, its work contributed significantly to the field of bioartificial organ development and extracorporeal life support.